¼¼°èÀÇ ¸ÞÆ®·Î´Ï´ÙÁ¹(Metronidazole) ½ÃÀå º¸°í¼­(2025³â)
Metronidazole Global Market Report 2025
»óǰÄÚµå : 1720831
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,265,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,056,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,846,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸ÞÆ®·Î´Ï´ÙÁ¹ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È Å« ÆøÀÇ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ¹ÚÅ׸®¾Æ ¹× ¿ø»ýµ¿¹° °¨¿°ÀÇ À¯º´·ü Áõ°¡, À§Àå Àå¾Ö »ç·Ê Áõ°¡, Àú·ÅÇÑ Á¦³×¸¯ Ç×»ýÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó È®´ë, Àü¿°º´ ÅðÄ¡¸¦ À§ÇÑ Á¤ºÎ ³ë·Â¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä Æ®·»µå¿¡´Â Á¦¾à Á¦Á¶ÀÇ ¹ßÀü, Á¦¾à ȸ»ç °£ÀÇ Àü·«Àû Çù¾÷, Á¦¾à À§Å¹ Á¦Á¶ Á¶Á÷ÀÇ È®´ë, ³ª³ë ±â¼ú ±â¹Ý ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Ã¤ÅÃ, pH ¹ÝÀÀ¼º ¸ÞÆ®·Î´Ï´ÙÁ¹ Á¦ÇüÀÇ Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù.

¹ÚÅ׸®¾Æ °¨¿°ÀÇ Áõ°¡´Â ¸ÞÆ®·Î´Ï´ÙÁ¹ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÚÅ׸®¾Æ °¨¿°Àº ü³» À¯ÇØ ¹ÚÅ׸®¾ÆÀÇ Áõ½ÄÀ¸·Î ÀÎÇØ ¹ß»ýÇϸç, Ç×»ýÁ¦ ³»¼º, ȯ°æ º¯È­ ¹× ¸é¿ª·ÂÀÌ ¾àÇÑ Àα¸ Áõ°¡¿Í °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸ÞÆ®·Î´Ï´ÙÁ¹Àº ¹ÚÅ׸®¾Æ DNA¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ º¹Á¦¿Í È®»êÀ» ¹æÇØÇÏ¿© Çø±â¼º ¹ÚÅ׸®¾Æ ¹× ƯÁ¤ ¿ø»ýµ¿¹° °¨¿°¿¡ ¸Å¿ì È¿°úÀûÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¿µ±¹ Á¤ºÎ ±â°üÀÎ ¿µ±¹ º¸°Ç¾Èº¸±¹(UKHSA)¿¡ µû¸£¸é 2022³â¿¡ ¿µ±¹¿¡¼­ Ç×»ýÁ¦ ³»¼º °¨¿°¿¡ °É¸° »ç¶÷Àº ¾à 5¸¸ 8,224¸íÀ¸·Î ÃßÁ¤µÇ¸ç, ÀÌ´Â 2021³â 5¸¸ 5,792¸í¿¡¼­ 4% Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ¶ÇÇÑ ÁßÁõ Ç×»ýÁ¦ ³»¼º °¨¿°À¸·Î ÀÎÇÑ »ç¸ÁÀÚ´Â 2021³â 2,110¸í¿¡¼­ 2022³â 2,202¸íÀ¸·Î Áõ°¡Çß½À´Ï´Ù. µû¶ó¼­ ¹ÚÅ׸®¾Æ °¨¿°ÀÇ À¯º´·ü Áõ°¡´Â ¸ÞÆ®·Î´Ï´ÙÁ¹ ½ÃÀåÀÇ È®ÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ÞÆ®·Î´Ï´ÙÁ¹ ½ÃÀåÀÇ ÁÖ¿ä ¾÷üµéÀº ȯÀÚ ¼øÀÀµµ¸¦ °³¼±Çϱâ À§ÇØ ¾à¹° Á¦ÇüÀ» ¹ßÀü½ÃŰ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ Á¤Á¦¸¦ »ïŰ±â ¾î·Æ°Å³ª º¸´Ù Æí¸®ÇÑ Ä¡·á ¿É¼ÇÀÌ ÇÊ¿äÇÑ È¯ÀÚ¸¦ À§ÇØ º¹¿ë ÆíÀǼºÀ» ³ôÀ̱â À§ÇØ Áï½Ã »ç¿ë °¡´ÉÇÑ ±¸°­ ¾×Á¦¿Í °°Àº Çõ½ÅÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¹Ù·Î »ç¿ëÇÒ ¼ö ÀÖ´Â °æ±¸¿ë ¾×Á¦´Â Ãß°¡ Áغñ³ª È¥ÇÕÀÌ ÇÊ¿ä ¾ø¾î º¹¾à ¼øÀÀµµ¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 11¿ù ¹Ì±¹°è Àü¹® Á¦¾àȸ»çÀÎ Kesin Pharma CorporationÀº 500mg/5mLÀÇ ¸ÞÆ®·Î´Ï´ÙÁ¹ °æ±¸ Çöʾ×ÀÎ ¶óÀÌÅ©¸ÞÁî¿¡ ´ëÇÑ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ »õ·Î¿î Á¦ÇüÀº ȯÀÚ ¼øÀÀµµ¸¦ °³¼±Çϵµ·Ï ¼³°èµÇ¾úÀ¸¸ç ¼ºÀΰú ¾î¸°ÀÌÀÇ Æ®¸®Äڸ𳪽ºÁõ ¹× Çø±â¼º ¼¼±Õ °¨¿°°ú ¾Æ¸Þ¹ÙÁõ Ä¡·áÁ¦·Î ½ÂÀεǾú½À´Ï´Ù. ¶óÀÌÅ©¸ÞÁî´Â µþ±â ÆäÆÛ¹ÎÆ® ÇâÀÇ Çöʾ×À¸·Î 200mL º´¿¡ ´ã°Ü ÀÖÀ¸¸ç À¯Åë±âÇÑÀº 24°³¿ùÀÌ°í ³ÃÀå º¸°üÀÌ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Metronidazole is an antibiotic and antiprotozoal medication used to treat bacterial and parasitic infections. It functions by penetrating microbial cells, where bacterial and protozoal enzymes reduce it, producing reactive nitrogen species. These reactive compounds damage DNA, leading to strand breakage and the inhibition of nucleic acid synthesis, ultimately disrupting replication and transcription, resulting in cell death.

The primary formulations of metronidazole include tablets, capsules, intravenous (IV) solutions, topical creams or ointments, and others. Metronidazole tablets are oral medications used to treat bacterial and parasitic infections, providing sustained effects for convenient and effective outpatient treatment. They are utilized for various applications, including bacterial infections, parasitic infections, gynecological infections, surgical prophylaxis, and more. The drug is distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. It is used by various end-users, including hospitals, clinics, homecare, and others.

The metronidazole market research report is one of a series of new reports from The Business Research Company that provides metronidazole market statistics, including the metronidazole industry global market size, regional shares, competitors with the metronidazole market share, detailed metronidazole market segments, market trends, and opportunities, and any further data you may need to thrive in the metronidazole industry. This metronidazole market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metronidazole market size has grown strongly in recent years. It will grow from $0.58 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to favorable healthcare reimbursement policies, increased funding for infectious disease research, a rising incidence of oral and dental infections, a growing prevalence of inflammatory bowel diseases, and an expanding elderly population.

The metronidazole market size is expected to see strong growth in the next few years. It will grow to $0.78 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to the rising prevalence of bacterial and protozoal infections, increasing cases of gastrointestinal disorders, growing demand for affordable generic antibiotics, expanding healthcare infrastructure, and government initiatives to combat infectious diseases. Key trends expected in this period include advancements in pharmaceutical manufacturing, strategic collaborations among pharmaceutical companies, the expansion of pharmaceutical contract manufacturing organizations, the adoption of nanotechnology-based drug delivery systems, and innovations in pH-responsive metronidazole formulations.

The rising incidence of bacterial infections is expected to drive the growth of the metronidazole market. Bacterial infections occur due to the proliferation of harmful bacteria in the body, and their increasing prevalence is attributed to factors such as antibiotic resistance, environmental changes, and a growing immunocompromised population. Metronidazole works by targeting bacterial DNA, disrupting its replication and spread, making it highly effective against anaerobic bacteria and certain protozoal infections. For instance, according to the UK Health Security Agency (UKHSA), a UK-based government agency, an estimated 58,224 individuals in England were affected by antibiotic-resistant infections in 2022, marking a 4% increase from 55,792 cases in 2021. Additionally, deaths from severe antibiotic-resistant infections rose from 2,110 in 2021 to 2,202 in 2022. As a result, the growing prevalence of bacterial infections is expected to fuel the expansion of the metronidazole market.

Key players in the metronidazole market are focusing on advancing drug formulations to improve patient compliance. Innovations such as ready-to-use oral liquids are being developed to enhance ease of administration, particularly for patients who have difficulty swallowing tablets or require a more convenient treatment option. Ready-to-use oral liquids eliminate the need for additional preparation or mixing, simplifying medication adherence. For example, in November 2023, Kesin Pharma Corporation, a US-based specialty pharmaceutical company, received FDA approval for LIKMEZ (metronidazole) oral suspension, 500 mg/5 mL. This novel formulation is designed to improve patient adherence and is approved for treating trichomoniasis and anaerobic bacterial infections in adults, as well as amebiasis in adults and children. LIKMEZ is available as a strawberry peppermint-flavored suspension in a 200 mL bottle with a 24-month shelf life and does not require refrigeration.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired a manufacturing facility from Teva Pharmaceutical Industries for an undisclosed amount. This acquisition is expected to double Marksans' existing production capacity from 8 billion units per year. Teva Pharmaceutical Industries is an India-based pharmaceutical company that manufactures metronidazole tablets.

Major players in the metronidazole market are Pfizer Inc., Merck & Co. Inc., Abbott Laboratories, Fresenius Kabi AG, Baxter International Inc., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., Zydus Lifesciences, YiChang HEC ChangJiang Pharmaceutical Co. Ltd., Aarti Drugs Ltd., Unichem Laboratories, Cosette Pharmaceuticals Inc., Saptalis Pharmaceuticals LLC, Huanggang Saikang Pharmaceutical Co. Ltd., Kesin Pharma, Hubei Hongyuan Pharmaceutical Technology Co. Ltd., Huanggang Yinhe Aarti Pharmaceutical Co. Ltd., and Higgs Healthcare.

Asia-Pacific was the largest region in the metronidazole market in 2024. The regions covered in metronidazole report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metronidazole market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metronidazole market consists of sales of oral suspension, suppositories, and gel. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metronidazole Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metronidazole market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for metronidazole ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metronidazole market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Metronidazole Market Characteristics

3. Metronidazole Market Trends And Strategies

4. Metronidazole Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metronidazole Growth Analysis And Strategic Analysis Framework

6. Metronidazole Market Segmentation

7. Metronidazole Market Regional And Country Analysis

8. Asia-Pacific Metronidazole Market

9. China Metronidazole Market

10. India Metronidazole Market

11. Japan Metronidazole Market

12. Australia Metronidazole Market

13. Indonesia Metronidazole Market

14. South Korea Metronidazole Market

15. Western Europe Metronidazole Market

16. UK Metronidazole Market

17. Germany Metronidazole Market

18. France Metronidazole Market

19. Italy Metronidazole Market

20. Spain Metronidazole Market

21. Eastern Europe Metronidazole Market

22. Russia Metronidazole Market

23. North America Metronidazole Market

24. USA Metronidazole Market

25. Canada Metronidazole Market

26. South America Metronidazole Market

27. Brazil Metronidazole Market

28. Middle East Metronidazole Market

29. Africa Metronidazole Market

30. Metronidazole Market Competitive Landscape And Company Profiles

31. Metronidazole Market Other Major And Innovative Companies

32. Global Metronidazole Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metronidazole Market

34. Recent Developments In The Metronidazole Market

35. Metronidazole Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â